Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast cancer patients after trastuzumab-based therapies. Approximately, 30% of invasive breast cancers (BC) overexpress HER2 ...

此外，基于 MP7 胃癌细胞的基因表达特征，研究人员预测了特定药物，并验证了 Taselisib 和 Lapatinib 对 MP7 胃癌细胞的抑制作用比相同浓度的常规药物 ...

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 Between May 29, 2015, and March 15, 2016, 128 eligible patients were ...

This was the day the FDA approved a novel compound, lapatinib, for patients with HER2–positive advanced or metastatic breast cancer who have received prior therapy including an anthracycline ...

December 28, 2006 — The experimental drug lapatinib (Tykerb, GlaxoSmithKline) doubled the median time to progression when added to capecitabine (Xeloda, Roche) in women with advanced HER2 ...

Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) will evaluate and compare the rate at which cancer cells disappear in the breast following treatment with lapatinib and ...

In all 3 trials, patients received treatment until disease progression. The EGF30008 trial compared lapatinib plus letrozole with letrozole alone. All patients in the trial (n=1,286, the ...

We checked this guidance and found nothing new that affects the recommendations. For more information, see the review decision. Next review: This guidance will be reviewed if there is new evidence ...

Amsterdam, The Netherlands: Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery ...

September 14, 2009 — Results from a phase 2 trial of lapatinib (Tykerb) in liver cancer were disappointing, with benefit seen only in a small subgroup of patients who developed a rash while ...